Detalhe da pesquisa
1.
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Blood
; 140(21): 2248-2260, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839452
2.
Primary Cutaneous Gamma-Delta T-Cell Lymphoma Mimicking anaplastic lymphoma kinase-1-Negative Anaplastic Large Cell Lymphoma: A Case Report.
Am J Dermatopathol
; 44(1): 62-65, 2022 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34889814
3.
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Clin Cancer Res
; 29(10): 1894-1905, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999993
4.
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm.
Am J Hematol
; 92(5): E75-E77, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28224664
5.
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
Nat Med
; 28(4): 735-742, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314842
6.
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.
Blood Adv
; 2(8): 933-940, 2018 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29685953